title: Prediction of oral drug absorption in humans by theoretical passive absorption model.
abstract: The purpose of the present study was to examine the oral drug absorption predictability of the theoretical passive absorption model (TPAM). As chemical descriptors of drugs, the octanol/buffer distribution coefficient at pH 6.0 (D(ow)), intrinsic octanol-water partition coefficient (P(ow)), pK(a), and molecular weight (MW) were calculated from the chemical structure. Total passive intestinal membrane permeation consists of transcellular, paracellular and unstirred water layer (UWL) permeation. Transcellular permeation was modeled based on the pH-partition hypothesis with correction for cationic species permeation, and the independent variables were D(ow), P(ow), and pK(a). Paracellular permeation was modeled as a size-restricted diffusion within a negative electrostatic field-of-force, and the independent variables were MW and pK(a). UWL permeation was modeled as diffusion across a water layer, and the independent variable was MW. Cationic species permeation in the transcellular permeation model and the effect of a negative electric field-of-force in the paracellular permeation model were the extensions to the previous TPAM. The coefficients of the paracellular and UWL permeation models were taken from the literature. A data set of 258 compounds with observed values of Fa% (the fraction of a dose absorbed in humans) taken from the literature was employed to optimize four fitting coefficients in the transcellular permeation model. The TPAM predicted Fa%, with root mean square errors of 15-21% and a correlation coefficient (CC) of 0.78-0.88. In addition, the TPAM predicted the effective human intestinal membrane permeability with a CC of 0.67-0.77, as well as the contribution of paracellular permeation. The TPAM was found to predict oral absorption from the chemical structure of drugs with adequate predictability for usage in drug discovery.
authors.affiliation: Pre-clinical Research Department I, Chugai Pharmaceutical Co. Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan. obatakuk@chugai-pharm.co.jp
authors.forename: Kouki
authors.initials: K
authors.lastname: Obata
authors.forename: Kiyohiko
authors.initials: K
authors.lastname: Sugano
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Saitoh
authors.forename: Atsuko
authors.initials: A
authors.lastname: Higashida
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Nabuchi
authors.forename: Minoru
authors.initials: M
authors.lastname: Machida
authors.forename: Yosinori
authors.initials: Y
authors.lastname: Aso
mesh_terms: D000284:Administration, Oral; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology*; D008956:Models, Chemical; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D011237:Predictive Value of Tests
chemical_list: D004364:Pharmaceutical Preparations